Cargando…
Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease represent some of the most prevalent neurodegenerative disorders afflicting millions of people worldwide. Unfortunately, there is a lack of efficacious treatments to cure or stop the progression of thes...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368966/ https://www.ncbi.nlm.nih.gov/pubmed/35955847 http://dx.doi.org/10.3390/ijms23158714 |
_version_ | 1784766308920852480 |
---|---|
author | De Plano, Laura M. Calabrese, Giovanna Conoci, Sabrina Guglielmino, Salvatore P. P. Oddo, Salvatore Caccamo, Antonella |
author_facet | De Plano, Laura M. Calabrese, Giovanna Conoci, Sabrina Guglielmino, Salvatore P. P. Oddo, Salvatore Caccamo, Antonella |
author_sort | De Plano, Laura M. |
collection | PubMed |
description | Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease represent some of the most prevalent neurodegenerative disorders afflicting millions of people worldwide. Unfortunately, there is a lack of efficacious treatments to cure or stop the progression of these disorders. While the causes of such a lack of therapies can be attributed to various reasons, the disappointing results of recent clinical trials suggest the need for novel and innovative approaches. Since its discovery, there has been a growing excitement around the potential for CRISPR-Cas9 mediated gene editing to identify novel mechanistic insights into disease pathogenesis and to mediate accurate gene therapy. To this end, the literature is rich with experiments aimed at generating novel models of these disorders and offering proof-of-concept studies in preclinical animal models validating the great potential and versatility of this gene-editing system. In this review, we provide an overview of how the CRISPR-Cas9 systems have been used in these neurodegenerative disorders. |
format | Online Article Text |
id | pubmed-9368966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93689662022-08-12 Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders De Plano, Laura M. Calabrese, Giovanna Conoci, Sabrina Guglielmino, Salvatore P. P. Oddo, Salvatore Caccamo, Antonella Int J Mol Sci Review Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease represent some of the most prevalent neurodegenerative disorders afflicting millions of people worldwide. Unfortunately, there is a lack of efficacious treatments to cure or stop the progression of these disorders. While the causes of such a lack of therapies can be attributed to various reasons, the disappointing results of recent clinical trials suggest the need for novel and innovative approaches. Since its discovery, there has been a growing excitement around the potential for CRISPR-Cas9 mediated gene editing to identify novel mechanistic insights into disease pathogenesis and to mediate accurate gene therapy. To this end, the literature is rich with experiments aimed at generating novel models of these disorders and offering proof-of-concept studies in preclinical animal models validating the great potential and versatility of this gene-editing system. In this review, we provide an overview of how the CRISPR-Cas9 systems have been used in these neurodegenerative disorders. MDPI 2022-08-05 /pmc/articles/PMC9368966/ /pubmed/35955847 http://dx.doi.org/10.3390/ijms23158714 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review De Plano, Laura M. Calabrese, Giovanna Conoci, Sabrina Guglielmino, Salvatore P. P. Oddo, Salvatore Caccamo, Antonella Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders |
title | Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders |
title_full | Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders |
title_fullStr | Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders |
title_full_unstemmed | Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders |
title_short | Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders |
title_sort | applications of crispr-cas9 in alzheimer’s disease and related disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368966/ https://www.ncbi.nlm.nih.gov/pubmed/35955847 http://dx.doi.org/10.3390/ijms23158714 |
work_keys_str_mv | AT deplanolauram applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders AT calabresegiovanna applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders AT conocisabrina applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders AT guglielminosalvatorepp applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders AT oddosalvatore applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders AT caccamoantonella applicationsofcrisprcas9inalzheimersdiseaseandrelateddisorders |